Binary Event Analysis: Outlook Therapeutics (OLTK) faces a critical PDUFA decision on December 31, 2025, for ONS-5010 (LYTENAVA™), a bevacizumab biosimilar for wet age-related macular degeneration (wet AMD).
Copy and paste this URL into your WordPress site to embed
